Cooper Companies Inc (NYSE:COO) – Investment analysts at Jefferies Financial Group boosted their FY2018 earnings estimates for Cooper Companies in a research note issued on Tuesday, December 4th. Jefferies Financial Group analyst A. Petrone now anticipates that the medical device company will post earnings per share of $11.58 for the year, up from their prior estimate of $11.56. Jefferies Financial Group also issued estimates for Cooper Companies’ Q4 2018 earnings at $2.94 EPS.

A number of other brokerages have also issued reports on COO. BMO Capital Markets lifted their price target on Cooper Companies from $280.00 to $285.00 and gave the stock an “outperform” rating in a research note on Friday, August 31st. Oppenheimer set a $270.00 price target on Cooper Companies and gave the company a “hold” rating in a research note on Friday, August 31st. Raymond James upped their price target on Cooper Companies from $270.00 to $300.00 and gave the company an “outperform” rating in a research note on Friday, September 21st. Zacks Investment Research downgraded Cooper Companies from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Finally, ValuEngine upgraded Cooper Companies from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $276.22.

Cooper Companies stock opened at $277.03 on Friday. The company has a market capitalization of $13.51 billion, a PE ratio of 28.56, a price-to-earnings-growth ratio of 2.11 and a beta of 0.77. Cooper Companies has a 12 month low of $216.47 and a 12 month high of $283.18. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.58 and a quick ratio of 1.54.

Cooper Companies (NYSE:COO) last announced its quarterly earnings results on Thursday, December 6th. The medical device company reported $2.87 earnings per share for the quarter, missing the consensus estimate of $2.96 by ($0.09). The company had revenue of $651.50 million for the quarter, compared to analysts’ expectations of $645.25 million. Cooper Companies had a net margin of 5.23% and a return on equity of 17.53%. The firm’s revenue was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.65 earnings per share.

In other Cooper Companies news, COO Daniel G. Mcbride sold 10,310 shares of the firm’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $264.44, for a total transaction of $2,726,376.40. Following the completion of the transaction, the chief operating officer now owns 38,705 shares of the company’s stock, valued at $10,235,150.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Randal Golden sold 1,731 shares of the firm’s stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $275.86, for a total value of $477,513.66. Following the transaction, the vice president now directly owns 1,154 shares of the company’s stock, valued at approximately $318,342.44. The disclosure for this sale can be found here. Insiders sold a total of 20,691 shares of company stock valued at $5,527,869 over the last ninety days. 1.60% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in COO. Dupont Capital Management Corp increased its position in Cooper Companies by 107.9% during the second quarter. Dupont Capital Management Corp now owns 1,125 shares of the medical device company’s stock worth $265,000 after buying an additional 584 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Cooper Companies by 0.4% during the second quarter. Victory Capital Management Inc. now owns 212,912 shares of the medical device company’s stock worth $50,129,000 after purchasing an additional 835 shares during the last quarter. Chevy Chase Trust Holdings Inc. acquired a new stake in shares of Cooper Companies during the second quarter worth $9,774,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Cooper Companies during the second quarter worth $9,685,000. Finally, KBC Group NV boosted its holdings in shares of Cooper Companies by 48.3% during the second quarter. KBC Group NV now owns 5,201 shares of the medical device company’s stock worth $1,225,000 after purchasing an additional 1,695 shares during the last quarter.

Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Further Reading: How does a reverse stock split work?

Earnings History and Estimates for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.